Treatment

Hizentra 200 mg/ml solution for subcutaneous injection clinical trials

4 indexed studies · 0 currently recruiting

Ongoing, recruitingPhase III and phase IV (Integrated)
Randomized, parallel study of subcutaneous versus intravenous immunoglobulin in treatment-naïve patients with chronic inflammatory demyelinating polyneuropathy
This study compares two ways of giving an important medicine for a nerve condition called CIDP. One way is an injection under the skin, and the other is through a drip into a vein. It looks at how well each method improves daily activities and muscle strength.
For: Chronic inflammatory demyelinating polyneuropathy (CIDP)
Denmark
Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM) – The RECLAIIM Study
This study is testing a new way to treat dermatomyositis, a condition that causes muscle weakness and skin problems. It will see how well a medicine called Hizentra works to improve symptoms and if it's safe, compared to a dummy treatment. We hope to find a better treatment for people with this condition.
For: Dermatomyositis
Hungary · France · Italy
Ongoing, recruitingTherapeutic confirmatory (Phase III)
Influencing Progression of Airway Disease in Primary Antibody Deficiency
This study looks at people with primary antibody deficiency to see if a higher dose of immunoglobulin (Ig) replacement therapy can slow down lung problems. We'll compare lung changes over two years using scans and other health measures. This could help improve treatment for these conditions.
Netherlands
Ongoing, recruitingTherapeutic confirmatory (Phase III)
Double-blind, Randomized, Placebo-controlled Phase 3 study Evaluating Efficacy and Safety of IgPro20 (subcutaneous immunoglobulin, HIZENTRA®) in post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS)
This study looks at a medicine called IgPro20 (Hizentra®) for people who have POTS after COVID-19. It aims to see if the medicine can reduce symptoms and make people feel better, compared to a dummy treatment.
For: Post-COVID-19 Postural Orthostatic Tachycardia Syndrome
Germany · Italy · Spain

Randomized, parallel study of subcutaneous versus intravenous immunoglobulin in treatment-naïve patients with chronic inflammatory demyelinating polyneuropathy

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM) – The RECLAIIM Study

Influencing Progression of Airway Disease in Primary Antibody Deficiency

Double-blind, Randomized, Placebo-controlled Phase 3 study Evaluating Efficacy and Safety of IgPro20 (subcutaneous immunoglobulin, HIZENTRA®) in post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS)